ROIV Stock — Roivant Sciences Ltd. Common Shares: Cash, EV, Pipeline

Share price

$39.77

Market cap

$28,726.8M

Cash

$3,842.1M

Enterprise value

$24,884.7M

Balance sheet

Cash	$3,842.1M
Debt	$0.0M
Net cash	$3,842.1M
Enterprise value	$24,884.7M
Basic shares	722.7M shares
Fully diluted shares	722.7M shares
Fully diluted market cap	$28,741.8M
Cash per share	$5.32

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading ROIV daily closes…

Loading price history…

Pipeline assets

IMVT-1402

Stage not disclosed · Active Modality: monoclonal antibody

Target FcRn

Partnerships HanAll Biopharma: core IP rights via the HanAll Agreement (Immunovant subsidiary)

Indications

Graves' disease (GD) (Stage not disclosed)
Difficult-to-treat rheumatoid arthritis (D2T RA) (Stage not disclosed)
Lichen planopilaris (LPP) (Stage not disclosed)

Status note Anti-FcRn antibody; the company's lead development program following discontinuation of batoclimab. Trials ongoing in D2T RA and other indications; filing references a potential launch in Graves' disease. No trial phase stated in the provided excerpts.

Brepocitinib

Phase 3 · Active Modality: small molecule

Target TYK2/JAK1

Partnerships Priovant (Roivant Vant); originally developed by Pfizer (other brepocitinib studies conducted by Pfizer)

Indications

Dermatomyositis (DM) (Phase 3)
Lichen planopilaris (LPP) (Phase 3)
Cutaneous sarcoidosis (CS) (Phase 2)

Catalysts

— None
— None
— None

Status note Oral TYK2/JAK1 inhibitor. FDA accepted the NDA in DM with Priority Review (target action date Q3 2026). Seamless Phase 2b/3 potentially registrational trial in LPP enrolled first subjects. Breakthrough Therapy Designation for cutaneous sarcoidosis (Phase 2 BEACON study complete).

Batoclimab

Phase 2 · Terminated Modality: monoclonal antibody

Target FcRn

Partnerships HanAll Biopharma: HanAll Agreement

Status note The company discontinued further development of batoclimab across all indications to focus fully on IMVT-1402.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Baker Bros. Advisors	4,716,831	-150,892	0.84%	2026-08-14
ADAR1 Capital Management	3,157,008	-128,898	5.25%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

ROIV — Roivant Sciences Ltd. Common Shares

Balance sheet

Price history

Pipeline assets

Institutional holders